FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/03/064020 [Registered on: 12/03/2024] Trial Registered Prospectively
Last Modified On: 17/04/2024
Post Graduate Thesis  Yes 
Type of Trial  Observational 
Type of Study   Follow Up Study 
Study Design  Single Arm Study 
Public Title of Study   Study to compare outcomes of Obstetric versus non Obstetric Acute Kidney Injury in a Tertiary Care Hospital  
Scientific Title of Study   Comparative Outcomes of Obstetric versus Non Obstetric Acute Kidney Injury in a Tertiary Care Hospital  
Trial Acronym  Nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Beauty Suman  
Designation  DM Senior Resident 
Affiliation  ATAL BIHARI VAJAPAYEE INSITUTE OF MEDICAL SCIENCE AND DR RAM MANOHAR LOHIA HOSPITAL  
Address  Department of Nephrology Atal Bihari Vajapayee institute of medical science and Dr Ram Manohar Lohia Hospital Baba Kharak Singh road New Delhi

New Delhi
DELHI
110001
India 
Phone  9953392829  
Fax    
Email  beautysuman.doc@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Lalit K Pursnani 
Designation  Professor 
Affiliation  ATAL BIHARI VAJAPAYEE INSTITUTE OF MEDICAL SCIENCES AND RAM MANOHAR LOHIA HOSPITAL  
Address  Department of Nephrology Atal Bihari vajapayee institute of medical science and Dr Ram Manohar Lohia Hospital Baba Kharak Singh Road New Delhi

New Delhi
DELHI
110001
India 
Phone  09958268930  
Fax    
Email  drlalitkpursnani@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Beauty Suman  
Designation  DM Resident  
Affiliation  ATAL BIHARI VAJAPAYEE INSTITUTE OF MEDICAL SCIENCES AND RAM MANOHAR LOHIA HOSPITAL  
Address  Department of Nephrology Atal Bihari Vajpayee institute of medical science and Dr Ram Manohar Lohia Hospital Baba Kharak Singh Road New Delhi

New Delhi
DELHI
110001
India 
Phone  9953392829  
Fax    
Email  beautysuman.doc@gmail.com  
 
Source of Monetary or Material Support  
Atal Bihari Vajpayee institute of medical science and Dr Ram Manohar Lohia Hospital New Delhi  
 
Primary Sponsor  
Name  Atal Bihari Vajpayee institute of medical science and Dr Ram Manohar Lohia Hospital  
Address  Department of Nephrology Atal Bihari Vajpayee institute of medical science and Dr Ram Manohar Lohia Hospital New Delhi-110001  
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Beauty Suman   Atal Bihari Vajpayee institute of medical science and Dr Ram Manohar Lohia Hospital   Department of Nephrology Atal Bihari Vajpayee institute of medical science and Dr Ram Manohar Lohia Hospital Baba Kharak Singh Road New Delhi-110001
New Delhi
DELHI 
9953392829

beautysuman.doc@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethic Committee, Atal Bihari Vajpayee institute of medical science and Dr Ram Manohar Lohia Hospital New Delhi   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: N17||Acute kidney failure,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Not applicable Its an observational study   Not applicable  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  Non obstetric cases:
A) rise in serum creatinine by more than 0.3mg/dl within 48 hours
B) rise in serum creatinine to more than 1.5 times baseline, which is known or presumed to have occured within the prior 7 days
C) urine volume less than 0.5ml/kg/h for 6 hours.
Obstetric cases:
All pregnant female and postpartum till 42 days with
A) rise in serum creatinine by more than 0.3mg/dl within 48 hours
B) rise in serum creatinine to more than 1.5 times baseline, which is known or presumed to have occured within the prior 7 days
C) urine volume less than 0.5ml/kg/h for 6 hours. 
 
ExclusionCriteria 
Details  1) patients with proven end stage renal disease
2) patients on maintenance hemodialysis
3) when baseline was not available and patient died before renal recovery
4) patients with known chronic kidney disease
5) renal transplant 
 
Method of Generating Random Sequence    
Method of Concealment    
Blinding/Masking    
Primary Outcome  
Outcome  TimePoints 
outcomes of acute kidney injury in obstetric and non obstetric cases in terms of dialysis dependency, progression to chronic kidney disease and mortality  outcomes of acute kidney injury in obstetric and non obstetric cases in terms of dialysis dependency, progression to chronic kidney disease and mortality at day 7, day 30 and day 90 
 
Secondary Outcome  
Outcome  TimePoints 
To study various etiologies of acute kidney injury presenting in a tertiary care hospital  follow up at dat 7, day 30 and day 90 
 
Target Sample Size   Total Sample Size="118"
Sample Size from India="118" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   20/03/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   Patients will be recruited  as per inclusion  and exclusion criteria  and all the details will be noted as per proforma.  Then Patient  will be followed  up at day 7, day 30 and day 90 for  outcomes.  
Close